Table 1. Overview of antimicrobial resistance and MLVA characteristics in relation to the phage type (n = 1,498).
| Phage type | Nb. isolates (% of total) | Nb. susceptible isolates (%) | Nb. MDR isolates (%) | Most common resistance patterns (% of isolates with resistance pattern) | Nb. MLVA types | Most common MLVA profiles (SENTR7-SENTR5-SENTR6-SENTR4-SE-3) (% of isolates with MLVA profile) |
|---|---|---|---|---|---|---|
| PT4 | 284 (19.0) | 253 (89,1) | 4 (1.4) | Amp (1.1), Nal (8.5) | 51 | 3–10–5–4–1 (38.2),3–11–5–4–1 (10.9) |
| PT8 | 279 (18.6) | 274 (98.2) | 1 (0.4) | Nal (0.4), Ctx (0.4), AmpCtxTetTmpSpeNalStrSulSxt (0.4) | 40 | 2–10–7–3–2 (35.5), 2–11–7–3–2 (14.3) |
| PT21 | 245 (16.3) | 235 (95.9) | 3 (1.2) | Nal (2.0) | 24 | 3–10–5–4–1 (27.7), 3–11–5–4–1 (27.3) |
| PT1 | 176 (11.7) | 137 (77.8) | 1 (0.6) | Nal (20.5), AmpAmxNal (1.1) | 28 | 3–10–5–4–1 (68.6) |
| PT6 | 127 (8.5) | 120 (94.5) | 1 (0.8) | Amp (10.2), Nal (3.9) | 24 | 3–10–5–4–1 (36.2), 3–9–5–4–1 (12.6), 3–10–5–3–1 (11.0) |
| PT14b | 69 (4.6) | 53 (76.8) | 1 (1.5) | Nal (21.7) | 15 | 2–13–7–3–2 (34.8), 3–10–5–4–1 (17.4) |
| PT28 | 61 (4.1) | 61 (100) | 0 (0) | - | 21 | 2–10–7–3–2 (44.3) |
| PT13 | 51 (3.4) | 27 (52.9) | 0 (0) | Nal (9.8) | 27 | 2–10–7–3–2 (15.7), 3–10–5–4–1 (7.8), 2–10–8–5–2 (7.8) |
| Other | 206 (13.7) | 162 (78.6) | 8 (3.9) | Nal (8.7), AmpTet (1.9) | 67 | 3–10–5–4–1 (17.9), 3–11–5–4–1 (9.2), 3–9–5–4–1 (7.7) |
MDR: multidrug resistant; MLVA: multiple-locus variable-number of tandem repeats analysis; Other: phage types with less than 3% occurrence in the isolate panel; Amp: ampicillin; Amx: amoxicillin plus clavulanic acid; Chl: chloramphenicol; Nal: nalidixic acid; Str: streptomycin; Sul: sulphonamides; Sxt: trimethoprim plus sulfamethoxazole, Tet: tetracycline; Tmp: trimethoprim